Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Breast Cancer

  Free Subscription


02.09.2019

6 Ann Surg Oncol
4 BMC Cancer
1 Breast Cancer
3 Breast Cancer Res
8 Breast Cancer Res Treat
7 Breast J
3 Cancer
1 Cancer Chemother Pharmacol
1 Cancer Epidemiol Biomarkers Prev
1 Cancer Lett
2 Clin Breast Cancer
1 Clin Med Insights Oncol
2 Eur J Cancer
1 Eur J Surg Oncol
1 Eur Radiol
1 Gene
1 Int J Cancer
1 Int J Oncol
3 J Clin Oncol
3 Oncogene
2 Oncology (Williston Park)
3 PLoS One
2 Radiology
2 Radiother Oncol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Surg Oncol

  1. MAMTANI A, Zabor EC, Rosenberger LH, Stempel M, et al
    Was Reexcision Less Frequent for Patients with Lobular Breast Cancer After Publication of the SSO-ASTRO Margin Guidelines?
    Ann Surg Oncol. 2019 Aug 27. pii: 10.1245/s10434-019-07751.
    PubMed     Text format     Abstract available

  2. MAMTANI A, Morrow M
    ASO Author Reflections: Early-Stage Lobular Breast Cancer: Axillary Treatment in the Z0011 Era.
    Ann Surg Oncol. 2019 Aug 29. pii: 10.1245/s10434-019-07769.
    PubMed     Text format    

  3. OZKURT E, Golshan M
    ASO Author Reflections: De-escalation of Breast Cancer Surgery-A Leap Forward.
    Ann Surg Oncol. 2019 Aug 29. pii: 10.1245/s10434-019-07759.
    PubMed     Text format    

  4. BARRIO AV, Brunelle C, Morrow M, Taghian AG, et al
    Letter to Editor re: Ridner et al.: "A Randomized Trial Evaluating Bioimpedance Spectroscopy Versus Tape Measurement for the Prevention of Lymphedema Following Treatment for Breast Cancer: Interim Analysis".
    Ann Surg Oncol. 2019 Aug 29. pii: 10.1245/s10434-019-07763.
    PubMed     Text format    

  5. ANKER AM, Prantl L, Strauss C, Brebant V, et al
    Assessment of DIEP Flap Perfusion with Intraoperative Indocyanine Green Fluorescence Imaging in Vasopressor-Dominated Hemodynamic Support Versus Liberal Fluid Administration: A Randomized Controlled Trial With Breast Cancer Patients.
    Ann Surg Oncol. 2019 Aug 29. pii: 10.1245/s10434-019-07758.
    PubMed     Text format     Abstract available

  6. MULLER HD, Posch F, Suppan C, Bargfrieder U, et al
    Validation of Residual Cancer Burden as Prognostic Factor for Breast Cancer Patients After Neoadjuvant Therapy.
    Ann Surg Oncol. 2019 Aug 26. pii: 10.1245/s10434-019-07741.
    PubMed     Text format     Abstract available


    BMC Cancer

  7. ZAKRZEWSKI F, Gieldon L, Rump A, Seifert M, et al
    Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples.
    BMC Cancer. 2019;19:396.
    PubMed     Text format     Abstract available

  8. ZENG L, Deng X, Zhong J, Yuan L, et al
    Prognostic value of biomarkers EpCAM and alphaB-crystallin associated with lymphatic metastasis in breast cancer by iTRAQ analysis.
    BMC Cancer. 2019;19:831.
    PubMed     Text format     Abstract available

  9. WONDIMAGEGNEHU A, Abebe W, Abraha A, Teferra S, et al
    Depression and social support among breast cancer patients in Addis Ababa, Ethiopia.
    BMC Cancer. 2019;19:836.
    PubMed     Text format     Abstract available

  10. CHAE BJ, Lee J, Lee SK, Shin HJ, et al
    Unmet needs and related factors of Korean breast cancer survivors: a multicenter, cross-sectional study.
    BMC Cancer. 2019;19:839.
    PubMed     Text format     Abstract available


    Breast Cancer

  11. DE SOUZA CUNHA N, Zomkowski K, Fernandes BL, Sacomori C, et al
    Physical symptoms and components of labor tasks associated with upper limb disability among working breast cancer survivors.
    Breast Cancer. 2019 Aug 27. pii: 10.1007/s12282-019-01004.
    PubMed     Text format     Abstract available


    Breast Cancer Res

  12. DE GROOT S, Pijl H, Charehbili A, van de Ven S, et al
    Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01).
    Breast Cancer Res. 2019;21:97.
    PubMed     Text format     Abstract available

  13. RAMANI VC, Lemaire CA, Triboulet M, Casey KM, et al
    Investigating circulating tumor cells and distant metastases in patient-derived orthotopic xenograft models of triple-negative breast cancer.
    Breast Cancer Res. 2019;21:98.
    PubMed     Text format     Abstract available

  14. MIAO Y, Shen Q, Zhang S, Huang H, et al
    Calcium-sensing stromal interaction molecule 2 upregulates nuclear factor of activated T cells 1 and transforming growth factor-beta signaling to promote breast cancer metastasis.
    Breast Cancer Res. 2019;21:99.
    PubMed     Text format     Abstract available


    Breast Cancer Res Treat

  15. KLUZNIAK W, Wokolorczyk D, Rusak B, Huzarski T, et al
    Inherited variants in XRCC2 and the risk of breast cancer.
    Breast Cancer Res Treat. 2019 Aug 28. pii: 10.1007/s10549-019-05415.
    PubMed     Text format     Abstract available

  16. D'AMBROSIO V, Vena F, Di Mascio D, Faralli I, et al
    Obstetrical outcomes in women with history of breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2019 Aug 26. pii: 10.1007/s10549-019-05408.
    PubMed     Text format     Abstract available

  17. CERRETINI R, Mercado G, Morganstein J, Schiaffi J, et al
    Germline pathogenic variants in BRCA1, BRCA2, PALB2 and RAD51C in breast cancer women from Argentina.
    Breast Cancer Res Treat. 2019 Aug 24. pii: 10.1007/s10549-019-05411.
    PubMed     Text format     Abstract available

  18. VERBEEK JGE, Atema V, Mewes JC, van Leeuwen M, et al
    Cost-utility, cost-effectiveness, and budget impact of Internet-based cognitive behavioral therapy for breast cancer survivors with treatment-induced menopausal symptoms.
    Breast Cancer Res Treat. 2019 Aug 26. pii: 10.1007/s10549-019-05410.
    PubMed     Text format     Abstract available

  19. DE BOER AZ, Bastiaannet E, de Glas NA, Marang-van de Mheen PJ, et al
    Effectiveness of radiotherapy after breast-conserving surgery in older patients with T1-2N0 breast cancer.
    Breast Cancer Res Treat. 2019 Aug 26. pii: 10.1007/s10549-019-05412.
    PubMed     Text format     Abstract available

  20. KUBO M, Kawai M, Kumamaru H, Miyata H, et al
    A population-based recurrence risk management study of patients with pT1 node-negative HER2+ breast cancer: a National Clinical Database study.
    Breast Cancer Res Treat. 2019 Aug 26. pii: 10.1007/s10549-019-05413.
    PubMed     Text format     Abstract available

  21. ZHI WI, Chen P, Kwon A, Chen C, et al
    Chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer survivors: a comparison of patient-reported outcomes and quantitative sensory testing.
    Breast Cancer Res Treat. 2019 Aug 27. pii: 10.1007/s10549-019-05416.
    PubMed     Text format     Abstract available

  22. CHEN J, Douglass J, Prasath V, Neace M, et al
    The microbiome and breast cancer: a review.
    Breast Cancer Res Treat. 2019 Aug 27. pii: 10.1007/s10549-019-05407.
    PubMed     Text format     Abstract available


    Breast J

  23. NAKHLIS F, Regan MM, Chun YS, Dominici LS, et al
    Patterns of breast reconstruction in patients diagnosed with inflammatory breast cancer: The Dana-Farber Cancer Institute's Inflammatory Breast Cancer Program experience.
    Breast J. 2019 Aug 25. doi: 10.1111/tbj.13509.
    PubMed     Text format     Abstract available

  24. HAMDY O, El-Badrawy A, Saleh GA, Metwally IH, et al
    Preoperative localization of sentinel lymph node in breast cancer patients by silver wire insertion or liquid charcoal injection guided by CT lymphography.
    Breast J. 2019 Aug 25. doi: 10.1111/tbj.13511.
    PubMed     Text format     Abstract available

  25. LA ROCCA E, Meneghini E, Dispinzieri M, Fiorentino A, et al
    Hypofractionated irradiation in 794 elderly breast cancer patients: An observational study.
    Breast J. 2019 Aug 25. doi: 10.1111/tbj.13489.
    PubMed     Text format     Abstract available

  26. GOOCH JC, Chun J, Kaplowitz E, Guth A, et al
    Pregnancy-associated breast cancer in a contemporary cohort of newly diagnosed women.
    Breast J. 2019 Aug 25. doi: 10.1111/tbj.13510.
    PubMed     Text format     Abstract available

  27. GELMON KA, Cristofanilli M, Rugo HS, DeMichele AM, et al
    Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
    Breast J. 2019 Aug 25. doi: 10.1111/tbj.13516.
    PubMed     Text format     Abstract available

  28. ARCIERO C, Buhariwalla K, Liu Y, Torres MA, et al
    Time from Completion of Neo-adjuvant Chemotherapy to Surgery: Effects on Outcomes in Breast Cancer Patients.
    Breast J. 2019 Aug 25. doi: 10.1111/tbj.13482.
    PubMed     Text format     Abstract available

  29. CHRISTIAN N, Heelan Gladden A, Friedman C, Gleisner-Patton A, et al
    Increasing omission of radiation therapy and sentinel node biopsy in elderly patients with early stage, hormone-positive breast cancer.
    Breast J. 2019 Aug 25. doi: 10.1111/tbj.13483.
    PubMed     Text format     Abstract available


    Cancer

  30. FREUND KM, Haas JS, Lemon SC, Burns White K, et al
    Standardized activities for lay patient navigators in breast cancer care: Recommendations from a citywide implementation study.
    Cancer. 2019 Aug 26. doi: 10.1002/cncr.32432.
    PubMed     Text format     Abstract available

  31. LEE J, Hur H, Lee JW, Youn HJ, et al
    Long-term risk of congestive heart failure in younger breast cancer survivors: A nationwide study by the SMARTSHIP group.
    Cancer. 2019 Aug 27. doi: 10.1002/cncr.32485.
    PubMed     Text format     Abstract available

  32. EWER SM, Pham DD
    Late-onset heart failure after treatment for breast cancer.
    Cancer. 2019 Aug 27. doi: 10.1002/cncr.32483.
    PubMed     Text format    


    Cancer Chemother Pharmacol

  33. NUTHALAPATI S, Stodtmann S, Shepherd SP, Ratajczak CK, et al
    Exposure-response analysis to inform the optimal dose of veliparib in combination with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer patients.
    Cancer Chemother Pharmacol. 2019 Aug 29. pii: 10.1007/s00280-019-03930.
    PubMed     Text format     Abstract available


    Cancer Epidemiol Biomarkers Prev

  34. REY-VARGAS L, Sanabria Salas MC, Fejerman L, Serrano-Gomez SJ, et al
    Risk factors for triple negative breast cancer among Latina women.
    Cancer Epidemiol Biomarkers Prev. 2019 Aug 27. pii: 1055-9965.EPI-19-0035.
    PubMed     Text format     Abstract available


    Cancer Lett

  35. QIU N, He YF, Zhang SM, Zhan YT, et al
    Cullin7 Enhances Resistance to Trastuzumab Therapy in Her2 Positive Breast Cancer via Degrading IRS-1 and Downregulating IGFBP-3 to Activate the PI3K/AKT Pathway.
    Cancer Lett. 2019 Aug 25. pii: S0304-3835(19)30439.
    PubMed     Text format     Abstract available


    Clin Breast Cancer

  36. WILKIE J, Schickli MA, Berger MJ, Lustberg M, et al
    Progression-Free Survival for Real-World Use of Palbociclib in Hormone Receptor-Positive Metastatic Breast Cancer.
    Clin Breast Cancer. 2019 Jul 17. pii: S1526-8209(19)30112.
    PubMed     Text format     Abstract available

  37. KOMOROWSKI AS, Warner E, MacKay HJ, Sahgal A, et al
    Incidence of Brain Metastases in Nonmetastatic and Metastatic Breast Cancer: Is There a Role for Screening?
    Clin Breast Cancer. 2019 Jul 11. pii: S1526-8209(18)30863.
    PubMed     Text format     Abstract available


    Clin Med Insights Oncol

  38. SARAVIA CH, Flores C, Schwarz LJ, Bravo L, et al
    Patterns of Mutation Enrichment in Metastatic Triple-Negative Breast Cancer.
    Clin Med Insights Oncol. 2019;13:1179554919868482.
    PubMed     Text format     Abstract available


    Eur J Cancer

  39. PIVOT X, Pegram M, Cortes J, Luftner D, et al
    Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer.
    Eur J Cancer. 2019;120:1-9.
    PubMed     Text format     Abstract available

  40. ROBSON M, Ruddy KJ, Im SA, Senkus E, et al
    Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial.
    Eur J Cancer. 2019;120:20-30.
    PubMed     Text format     Abstract available


    Eur J Surg Oncol

  41. GARCIA-ETIENNE CA, Ferrari A, Della Valle A, Lucioni M, et al
    Management of the axilla in patients with breast cancer and positive sentinel lymph node biopsy: An evidence-based update in a European breast center.
    Eur J Surg Oncol. 2019 Aug 13. pii: S0748-7983(19)30628.
    PubMed     Text format     Abstract available


    Eur Radiol

  42. IOTTI V, Giorgi Rossi P, Nitrosi A, Ravaioli S, et al
    Comparing two visualization protocols for tomosynthesis in screening: specificity and sensitivity of slabs versus planes plus slabs.
    Eur Radiol. 2019;29:3802-3811.
    PubMed     Text format     Abstract available


    Gene

  43. WANG H, Xu B, Shi J
    N6-methyladenosine METTL3 promotes the breast cancer progression via targeting Bcl-2.
    Gene. 2019 Aug 24:144076. doi: 10.1016/j.gene.2019.144076.
    PubMed     Text format     Abstract available


    Int J Cancer

  44. PRAJZENDANC K, Domagala P, Hybiak J, Rys J, et al
    BRCA1 promoter methylation in peripheral blood is associated with the risk of triple-negative breast cancer.
    Int J Cancer. 2019 Aug 30. doi: 10.1002/ijc.32655.
    PubMed     Text format     Abstract available


    Int J Oncol

  45. CHENG S, Castillo V, Sliva D
    CDC20 associated with cancer metastasis and novel mushroomderived CDC20 inhibitors with antimetastatic activity.
    Int J Oncol. 2019;54:2250-2256.
    PubMed     Text format     Abstract available


    J Clin Oncol

  46. HINDIE E
    Skipping the Lymphoscintigraphy Step During Sentinel Node Procedures in Breast Cancer: What Information Are We Missing?
    J Clin Oncol. 2019 Aug 29:JCO1901612. doi: 10.1200/JCO.19.01612.
    PubMed     Text format    

  47. LITTON JK, Scoggins ME, Hess KR, Adrada BE, et al
    Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant.
    J Clin Oncol. 2019 Aug 28:JCO1901304. doi: 10.1200/JCO.19.01304.
    PubMed     Text format     Abstract available

  48. JIMENEZ RB, Hickey S, DePauw N, Yeap BY, et al
    Phase II Study of Proton Beam Radiation Therapy for Patients With Breast Cancer Requiring Regional Nodal Irradiation.
    J Clin Oncol. 2019 Aug 26:JCO1802366. doi: 10.1200/JCO.18.02366.
    PubMed     Text format     Abstract available


    Oncogene

  49. YAO N, Fu Y, Chen L, Liu Z, et al
    Long non-coding RNA NONHSAT101069 promotes epirubicin resistance, migration, and invasion of breast cancer cells through NONHSAT101069/miR-129-5p/Twist1 axis.
    Oncogene. 2019 Aug 23. pii: 10.1038/s41388-019-0904.
    PubMed     Text format     Abstract available

  50. CEBRIA-COSTA JP, Pascual-Reguant L, Gonzalez-Perez A, Serra-Bardenys G, et al
    LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple-negative breast cancer cells.
    Oncogene. 2019 Aug 28. pii: 10.1038/s41388-019-0969.
    PubMed     Text format     Abstract available

  51. SIRKISOON SR, Carpenter RL, Rimkus T, Doheny D, et al
    TGLI1 transcription factor mediates breast cancer brain metastasis via activating metastasis-initiating cancer stem cells and astrocytes in the tumor microenvironment.
    Oncogene. 2019 Aug 28. pii: 10.1038/s41388-019-0959.
    PubMed     Text format     Abstract available


    Oncology (Williston Park)

  52. COPUR MS
    Universal Genetic Testing for All Breast Cancer Patients.
    Oncology (Williston Park). 2019;33.
    PubMed     Text format     Abstract available

  53. KRISHNAN M, Krishnamurthy J, Shonka N
    Targeting the Sanctuary Site: Options when Breast Cancer Metastasizes to the Brain.
    Oncology (Williston Park). 2019;33.
    PubMed     Text format     Abstract available


    PLoS One

  54. TIAN W, Yao Y, Fan G, Zhou Y, et al
    Changes in lipid profiles during and after (neo)adjuvant chemotherapy in women with early-stage breast cancer: A retrospective study.
    PLoS One. 2019;14:e0221866.
    PubMed     Text format     Abstract available

  55. YOON CI, Ahn SG, Bae SJ, Shin YJ, et al
    High A20 expression negatively impacts survival in patients with breast cancer.
    PLoS One. 2019;14:e0221721.
    PubMed     Text format     Abstract available

  56. CLEMENT-ZHAO A, Tanguy ML, Cottu P, De La Lande B, et al
    Toxicity of locoregional radiotherapy in combination with bevacizumab in patients with non-metastatic breast cancer (TOLERAB): Final long-term evaluation.
    PLoS One. 2019;14:e0221816.
    PubMed     Text format     Abstract available


    Radiology

  57. NEWELL MS
    Risk versus Benefit of Surveillance Breast MRI: A Sticky Wicket.
    Radiology. 2019 Jun 4:190991. doi: 10.1148/radiol.2019190991.
    PubMed     Text format    

  58. SUNG JS, Lebron L, Keating D, D'Alessio D, et al
    Performance of Dual-Energy Contrast-enhanced Digital Mammography for Screening Women at Increased Risk of Breast Cancer.
    Radiology. 2019 Aug 27:182660. doi: 10.1148/radiol.2019182660.
    PubMed     Text format     Abstract available


    Radiother Oncol

  59. MUTTER RW
    ESTRO ACROP consensus guideline for target volume delineation in the setting of postmastectomy radiation therapy after implant-based immediate reconstruction for early stage breast cancer.
    Radiother Oncol. 2019 Aug 23. pii: S0167-8140(19)33012.
    PubMed     Text format    

  60. KAIDAR-PERSON O, Offersen BV, Poortmans P
    Should risk-adapted delineation considered de-escalation of therapy? The ESTRO-ACROP radiation therapy guidelines after implant-based immediate reconstruction for early stage breast cancer.
    Radiother Oncol. 2019 Aug 23. pii: S0167-8140(19)33025.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: